TY - JOUR
T1 - Impact of minimally invasive surgery on the treatment of esophageal achalasia
T2 - A decade of change
AU - Patti, Marco G.
AU - Fisichella, Piero M.
AU - Perretta, Silvana
AU - Galvani, Carlos
AU - Gorodner V, Maria
AU - Robinson, Thomas
AU - Way, Lawrence W.
AU - MacFadyen, Bruce V.
PY - 2003/5/1
Y1 - 2003/5/1
N2 - BACKGROUND: Twenty years ago an average of 1.5 Heller myotomies were performed per year in our hospital, mostly for patients whose dysphagia did not improve following balloon dilatation or whose esophagus had been perforated during a balloon dilatation. Ten years ago we started using minimally invasive surgery to treat this disease. STUDY DESIGN: This study measures the impact of minimally invasive surgery with regard to the following: the number of patients referred for treatment; the number of patients who came to surgery without previous treatment; and the results of surgical treatment. Between 1991 and 2001, 149 patients had minimally invasive surgery for achalasia: 25 patients (17%) had thoracoscopic Heller myotomy and 124 (84%) had laparoscopic Heller myotomy and Dor fundoplication. Of the 149 patients, 79 patients (53%) had previous treatment (56 patients [71%], balloon dilatation; 7 patients [9%], botulinum toxin injection; 16 patients [20%], both) and 70 patients (43%) had none of these treatments. Mean postoperative followup was 59 ± 36 months. Patients were divided into two groups: group A, operated on between 1991 and 1995; and group B, operated on between 1996 and 2001. RESULTS: In the past decade, the number of patients referred for surgery has increased substantially - group A, 48; group B, 101; an increasing proportion of patients were referred for surgery without previous treatment - group A, 38%; group B, 51%; and the outcomes of the operation progressively improved - group A, 87%; group B, 95%. CONCLUSIONS: These data show that the high success rate of laparoscopic Heller myotomy for achalasia has brought a shift in practice; surgery has become the preferred treatment of most gastroenterologists and other referring physicians. This has followed documentation that laparoscopic treatment outperforms balloon dilatation and botulinum toxin injection.
AB - BACKGROUND: Twenty years ago an average of 1.5 Heller myotomies were performed per year in our hospital, mostly for patients whose dysphagia did not improve following balloon dilatation or whose esophagus had been perforated during a balloon dilatation. Ten years ago we started using minimally invasive surgery to treat this disease. STUDY DESIGN: This study measures the impact of minimally invasive surgery with regard to the following: the number of patients referred for treatment; the number of patients who came to surgery without previous treatment; and the results of surgical treatment. Between 1991 and 2001, 149 patients had minimally invasive surgery for achalasia: 25 patients (17%) had thoracoscopic Heller myotomy and 124 (84%) had laparoscopic Heller myotomy and Dor fundoplication. Of the 149 patients, 79 patients (53%) had previous treatment (56 patients [71%], balloon dilatation; 7 patients [9%], botulinum toxin injection; 16 patients [20%], both) and 70 patients (43%) had none of these treatments. Mean postoperative followup was 59 ± 36 months. Patients were divided into two groups: group A, operated on between 1991 and 1995; and group B, operated on between 1996 and 2001. RESULTS: In the past decade, the number of patients referred for surgery has increased substantially - group A, 48; group B, 101; an increasing proportion of patients were referred for surgery without previous treatment - group A, 38%; group B, 51%; and the outcomes of the operation progressively improved - group A, 87%; group B, 95%. CONCLUSIONS: These data show that the high success rate of laparoscopic Heller myotomy for achalasia has brought a shift in practice; surgery has become the preferred treatment of most gastroenterologists and other referring physicians. This has followed documentation that laparoscopic treatment outperforms balloon dilatation and botulinum toxin injection.
UR - https://www.scopus.com/pages/publications/0037989674
UR - https://www.scopus.com/inward/citedby.url?scp=0037989674&partnerID=8YFLogxK
U2 - 10.1016/S1072-7515(02)01837-9
DO - 10.1016/S1072-7515(02)01837-9
M3 - Article
C2 - 12742198
AN - SCOPUS:0037989674
SN - 1072-7515
VL - 196
SP - 698
EP - 703
JO - Journal of the American College of Surgeons
JF - Journal of the American College of Surgeons
IS - 5
ER -